• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BUPROPION Drug Record

  • Summary
  • Interactions
  • Claims
  • BUPROPION chembl:CHEMBL894 Approved

    Alternate Names:

    BUPROPION
    AMFEBUTAMONE
    ZYBAN®
    BW-323
    WELLBUTRIN®
    chembl:CHEMBL894
    rxcui:42347
    drugbank:01156
    chemidplus:34911-55-2
    pubchem.compound:444

    Drug Info:

    Drug Class antidepressive agents
    Year of Approval 1985
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant,appetite suppressant,smoking-cessation agent
    (2 More Sources)

    Publications:

    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
    Stahl et al., 2004, A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor., Prim Care Companion J Clin Psychiatry
    Bondarev et al., 2003, Behavioral and biochemical investigations of bupropion metabolites., Eur. J. Pharmacol.
    Mitchell et al., 2006, The effects of norepinephrine transporter inactivation on locomotor activity in mice., Biol. Psychiatry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Shalabi AR et al., 2017, Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release., ACS Chem Neurosci
    Mortensen OV et al., 2006, Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters., J Neurochem
    de Greef et al., 1987, Control of prolactin release induced by suckling., Endocrinology
    Miller et al., 2002, Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine., J. Pharmacol. Exp. Ther.
    Kugaya et al., 2003, Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration., Neuropsychopharmacology
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Szabó et al., 2004, [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]., Neuropsychopharmacol Hung
    Meyer et al., 2002, Bupropion occupancy of the dopamine transporter is low during clinical treatment., Psychopharmacology (Berl.)
    Learned-Coughlin et al., 2003, In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography., Biol. Psychiatry
    Simonsen U et al., 2016, Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction., Basic Clin Pharmacol Toxicol
    Bergen AW et al., 2015, Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption., PLoS One
    Tomaz PR et al., 2015, CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy., Eur J Clin Pharmacol
    Choi HD et al., 2015, Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis., Int J Clin Pharmacol Ther
    David SP et al., 2007, Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials., Nicotine Tob Res
    David SP et al., 2007, Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation., Nicotine Tob Res
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Lerman C et al., 2003, Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial., Health Psychol
    Quaak M et al., 2012, Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation., Addiction
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
    Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
    Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
    Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
    Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
    Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
    Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
    Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
    Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
    Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
    Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
    Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
    Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
    Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
    Berrettini WH et al., 2007, Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence., Biol Psychiatry
    Clark SL et al., 2012, Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D., Psychol Med
  • BUPROPION   SACM1L

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22041458


    Sources:
    PharmGKB

  • BUPROPION   ANKK1

    Interaction Score: 2.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26153084 25881752 18058343 17654295 15492764 14570538


    Sources:
    PharmGKB

  • BUPROPION   EPB41

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • BUPROPION   GALR1

    Interaction Score: 1.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • BUPROPION   DBH

    Interaction Score: 1.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • BUPROPION   SLC6A3

    Interaction Score: 0.93

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BVF-033,Aplenzin
    Novel drug target Established target
    Trial Name Contrave

    PMIDs:
    12183670 12589396 9537821 15787205 12185406 14550679 11752352 15361919 28220701 16923164 27541930


    Sources:
    TdgClinicalTrial TEND

  • BUPROPION   SLC6A2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BVF-033,Aplenzin
    Novel drug target Established target
    Trial Name Contrave

    PMIDs:
    15361919 12909199 16893531 11752352 28220701 16923164


    Sources:
    TdgClinicalTrial TEND

  • BUPROPION   DRD2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123753 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405


    Sources:
    PharmGKB

  • BUPROPION   FKBP5

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • BUPROPION   SLC18A2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • BUPROPION   CYP2A6

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26132489


    Sources:
    PharmGKB

  • BUPROPION   COMT

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16876132


    Sources:
    PharmGKB

  • BUPROPION   PRL

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3109881


    Sources:
    NCI

  • BUPROPION   SLC6A4

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21658141


    Sources:
    PharmGKB

  • BUPROPION   ACE

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • BUPROPION   HTR2A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • BUPROPION   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: BUPROPION

    • Version: 01-August-2011

    Alternate Names:
    BUPROPION Primary Drug Name

    Drug Info:
    Year of Approval 1985
    Drug Class antidepressive agents

    Publications:

  • TdgClinicalTrial: BUPROPION

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant,appetite suppressant,smoking-cessation agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: BUPROPION

    • Version: 14-September-2017

    Alternate Names:
    C1317 NCI drug code

    Drug Info:

    Publications:
    de Greef et al., 1987, Control of prolactin release induced by suckling., Endocrinology

  • PharmGKB: bupropion

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Choi HD et al., 2015, Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis., Int J Clin Pharmacol Ther

  • TTD: Bupropion

    • Version: 2020.06.01

    Alternate Names:
    D0X4ZR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL894

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21